Genome editing in lysosomal disorders
Progress in Molecular Biology and Translational Science, ISSN: 1877-1173, Vol: 182, Page: 289-325
2021
- 1Citations
- 12Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations1
- Citation Indexes1
- CrossRef1
- Captures12
- Readers12
- 12
Article Description
Lysosomal disorders are a group of heterogenous diseases caused by mutations in genes that encode for lysosomal proteins. With exception of some cases, these disorders still lack both knowledge of disease pathogenesis and specific therapies. In this sense, genome editing arises as a technique that allows both the creation of specific cell lines, animal models and gene therapy protocols for these disorders. Here we explain the main applications of genome editing for lysosomal diseases, with examples based on the literature. The ability to rewrite the genome will be of extreme importance to study and potentially treat these rare disorders.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1877117321000429; http://dx.doi.org/10.1016/bs.pmbts.2021.02.001; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85101384935&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/34175045; https://linkinghub.elsevier.com/retrieve/pii/S1877117321000429; https://dx.doi.org/10.1016/bs.pmbts.2021.02.001
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know